Particular CSF sphingolipid patterns identify iNPH and AD patients

Enrica Torretta, Beatrice Arosio, Pietro Barbacini, Martina Casati, Daniele Capitanio, Roberta Mancuso, Daniela Mari, Matteo Cesari, Mario Clerici, Cecilia Gelfi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Idiopathic normal pressure hydrocephalus (iNPH) is characterized by reversible neurological symptoms due to an impairment in cerebrospinal fluid (CSF) clearance. In these patients, cognitive functions are severely impaired, with a scenario similar to Alzheimer’s disease (AD), making the differential diagnosis difficult and highlighting the need of new markers. We analyzed the composition of sphingolipids (SLs) in serum, by combining a single phase extraction with a high-performance thin-layer chromatography (HPTLC) primuline-profiling, and, in CSF, by MALDI profiling and LC-MS. Ceramides and sphingomyelins (SMs) were similar in serum of iNPH and AD patients compared to healthy controls, whereas, in CSF, MALDI profiling indicated that: 1) SM C24:1 is significantly decreased in AD compared to iNPH patients and controls (Kruskal-Wallis p-value < 0.00001); 2) phosphatidylcholine (PC) 36:2 is increased in iNPH patients (p-value < 0.001). LC-MS identified an increasing trend of Cer C24:0 and of a set of SMs in patients with AD, a significant decrease of sphingosine-1-phosphate (S1P) (t-test p-value 0.0325) and an increase of glucosylceramide (GlcCer) C24:0 (p-value 0.0037) in AD compared to iNPH patients. In conclusion CSF PC 36:2, SM C24:1, S1P, and GlcCer can contribute to improve the differential diagnosis of patients with iNPH or AD and foster preventive therapeutic strategies in the early phase of the disease.

Original languageEnglish
Article number13639
JournalScientific Reports
Volume8
Issue number1
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Normal Pressure Hydrocephalus
Sphingolipids
Cerebrospinal Fluid
Alzheimer Disease
Sphingomyelins
Glucosylceramides
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Phosphatidylcholines
Differential Diagnosis
Ceramides
Thin Layer Chromatography
Serum
Cognition

ASJC Scopus subject areas

  • General

Cite this

Particular CSF sphingolipid patterns identify iNPH and AD patients. / Torretta, Enrica; Arosio, Beatrice; Barbacini, Pietro; Casati, Martina; Capitanio, Daniele; Mancuso, Roberta; Mari, Daniela; Cesari, Matteo; Clerici, Mario; Gelfi, Cecilia.

In: Scientific Reports, Vol. 8, No. 1, 13639, 01.12.2018.

Research output: Contribution to journalArticle

Torretta, Enrica ; Arosio, Beatrice ; Barbacini, Pietro ; Casati, Martina ; Capitanio, Daniele ; Mancuso, Roberta ; Mari, Daniela ; Cesari, Matteo ; Clerici, Mario ; Gelfi, Cecilia. / Particular CSF sphingolipid patterns identify iNPH and AD patients. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{a194d9a6674a43909e9ef35c4663d05f,
title = "Particular CSF sphingolipid patterns identify iNPH and AD patients",
abstract = "Idiopathic normal pressure hydrocephalus (iNPH) is characterized by reversible neurological symptoms due to an impairment in cerebrospinal fluid (CSF) clearance. In these patients, cognitive functions are severely impaired, with a scenario similar to Alzheimer’s disease (AD), making the differential diagnosis difficult and highlighting the need of new markers. We analyzed the composition of sphingolipids (SLs) in serum, by combining a single phase extraction with a high-performance thin-layer chromatography (HPTLC) primuline-profiling, and, in CSF, by MALDI profiling and LC-MS. Ceramides and sphingomyelins (SMs) were similar in serum of iNPH and AD patients compared to healthy controls, whereas, in CSF, MALDI profiling indicated that: 1) SM C24:1 is significantly decreased in AD compared to iNPH patients and controls (Kruskal-Wallis p-value < 0.00001); 2) phosphatidylcholine (PC) 36:2 is increased in iNPH patients (p-value < 0.001). LC-MS identified an increasing trend of Cer C24:0 and of a set of SMs in patients with AD, a significant decrease of sphingosine-1-phosphate (S1P) (t-test p-value 0.0325) and an increase of glucosylceramide (GlcCer) C24:0 (p-value 0.0037) in AD compared to iNPH patients. In conclusion CSF PC 36:2, SM C24:1, S1P, and GlcCer can contribute to improve the differential diagnosis of patients with iNPH or AD and foster preventive therapeutic strategies in the early phase of the disease.",
author = "Enrica Torretta and Beatrice Arosio and Pietro Barbacini and Martina Casati and Daniele Capitanio and Roberta Mancuso and Daniela Mari and Matteo Cesari and Mario Clerici and Cecilia Gelfi",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-31756-0",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Particular CSF sphingolipid patterns identify iNPH and AD patients

AU - Torretta, Enrica

AU - Arosio, Beatrice

AU - Barbacini, Pietro

AU - Casati, Martina

AU - Capitanio, Daniele

AU - Mancuso, Roberta

AU - Mari, Daniela

AU - Cesari, Matteo

AU - Clerici, Mario

AU - Gelfi, Cecilia

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Idiopathic normal pressure hydrocephalus (iNPH) is characterized by reversible neurological symptoms due to an impairment in cerebrospinal fluid (CSF) clearance. In these patients, cognitive functions are severely impaired, with a scenario similar to Alzheimer’s disease (AD), making the differential diagnosis difficult and highlighting the need of new markers. We analyzed the composition of sphingolipids (SLs) in serum, by combining a single phase extraction with a high-performance thin-layer chromatography (HPTLC) primuline-profiling, and, in CSF, by MALDI profiling and LC-MS. Ceramides and sphingomyelins (SMs) were similar in serum of iNPH and AD patients compared to healthy controls, whereas, in CSF, MALDI profiling indicated that: 1) SM C24:1 is significantly decreased in AD compared to iNPH patients and controls (Kruskal-Wallis p-value < 0.00001); 2) phosphatidylcholine (PC) 36:2 is increased in iNPH patients (p-value < 0.001). LC-MS identified an increasing trend of Cer C24:0 and of a set of SMs in patients with AD, a significant decrease of sphingosine-1-phosphate (S1P) (t-test p-value 0.0325) and an increase of glucosylceramide (GlcCer) C24:0 (p-value 0.0037) in AD compared to iNPH patients. In conclusion CSF PC 36:2, SM C24:1, S1P, and GlcCer can contribute to improve the differential diagnosis of patients with iNPH or AD and foster preventive therapeutic strategies in the early phase of the disease.

AB - Idiopathic normal pressure hydrocephalus (iNPH) is characterized by reversible neurological symptoms due to an impairment in cerebrospinal fluid (CSF) clearance. In these patients, cognitive functions are severely impaired, with a scenario similar to Alzheimer’s disease (AD), making the differential diagnosis difficult and highlighting the need of new markers. We analyzed the composition of sphingolipids (SLs) in serum, by combining a single phase extraction with a high-performance thin-layer chromatography (HPTLC) primuline-profiling, and, in CSF, by MALDI profiling and LC-MS. Ceramides and sphingomyelins (SMs) were similar in serum of iNPH and AD patients compared to healthy controls, whereas, in CSF, MALDI profiling indicated that: 1) SM C24:1 is significantly decreased in AD compared to iNPH patients and controls (Kruskal-Wallis p-value < 0.00001); 2) phosphatidylcholine (PC) 36:2 is increased in iNPH patients (p-value < 0.001). LC-MS identified an increasing trend of Cer C24:0 and of a set of SMs in patients with AD, a significant decrease of sphingosine-1-phosphate (S1P) (t-test p-value 0.0325) and an increase of glucosylceramide (GlcCer) C24:0 (p-value 0.0037) in AD compared to iNPH patients. In conclusion CSF PC 36:2, SM C24:1, S1P, and GlcCer can contribute to improve the differential diagnosis of patients with iNPH or AD and foster preventive therapeutic strategies in the early phase of the disease.

UR - http://www.scopus.com/inward/record.url?scp=85053246396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053246396&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-31756-0

DO - 10.1038/s41598-018-31756-0

M3 - Article

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 13639

ER -